GLP1R and diabetes mellitus: Patients with diabetes treated with insulin or the glucagon-like peptide 1 receptor agonist (GLP-1RA) are recommended to perform self-monitoring of blood glucose (SMBG), which is covered by health insurance in Japan, to achieve and maintain blood glucose within the normal range as much as possible [1-5].